Grant ID RP190002
Awarded On February 21, 2019
Title Development of a Precision Drug to Target STAG2 (SA2)–Mutant Ewing Sarcoma
Program Academic Research
Award Mechanism Individual Investigator Research Awards for Cancer in Children and Adolescents
Institution/Organization Baylor College of Medicine
Principal Investigator/Program Director Debananda Pati
Cancer Sites Bone, Brain and Other Nervous System, Leukemia
Contracted Amount $1,189,218*

*Pending contract negotiation

Lay Summary

Currently, no good therapy exists for Ewing Sarcoma (EWS), a type of bone cancer in children and adolescents that has an aggressive disease phenotype and poor prognosis. EWS occurs most commonly in the second decade of life, with a rate of 0.3 cases per million in children younger than 3 years of age, and as high as 4.6 cases per million in adolescents aged 15–19 years. Long-term survival for metastatic EWS is <20%. A rare pediatric cancer, EWS has received little attention from researchers and less interest from pharmaceuticals to develop new drugs. Our goal is to develop a precision therapy against EWS that is safe and effective with minimal side effects, and which spares normal develop...

Read More